Chelsea Counsel Co. Has $3.09 Million Position in Amgen Inc. $AMGN

Chelsea Counsel Co. lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 15.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,949 shares of the medical research company’s stock after selling 1,933 shares during the period. Amgen accounts for 1.4% of Chelsea Counsel Co.’s holdings, making the stock its 21st biggest position. Chelsea Counsel Co.’s holdings in Amgen were worth $3,090,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Trust Investment Advisors boosted its position in Amgen by 3.3% during the third quarter. Trust Investment Advisors now owns 3,713 shares of the medical research company’s stock worth $1,048,000 after purchasing an additional 118 shares during the period. Burkett Financial Services LLC increased its holdings in shares of Amgen by 2.9% in the third quarter. Burkett Financial Services LLC now owns 2,021 shares of the medical research company’s stock valued at $570,000 after purchasing an additional 57 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Amgen in the third quarter valued at about $26,516,000. Achmea Investment Management B.V. raised its position in shares of Amgen by 0.4% in the third quarter. Achmea Investment Management B.V. now owns 202,584 shares of the medical research company’s stock valued at $57,170,000 after purchasing an additional 870 shares during the period. Finally, WBI Investments LLC lifted its stake in shares of Amgen by 193.0% during the 3rd quarter. WBI Investments LLC now owns 2,628 shares of the medical research company’s stock worth $742,000 after buying an additional 1,731 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported stronger-than-expected results and raised FY guidance, supporting fundamentals and cash flow — a key reason some investors remain constructive. MarketBeat Earnings & Guidance
• Positive Sentiment: Analysts lifted Amgen’s fair-value estimate on growing confidence in execution and the MariTide obesity program, which boosts upside expectations if clinical/exclusivity risks are managed. Yahoo: Narrative Shifting
• Positive Sentiment: Large investor interest: Ken Fisher’s firm increased its Amgen stake, a vote of confidence from a prominent institutional investor. Yahoo: Ken Fisher Doubles Position
• Neutral Sentiment: Amgen is being watched by retail and professional traders (trending coverage), which can amplify moves but doesn’t by itself change fundamentals. Zacks: Trending Stock
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent/zeroed out and is not signaling a clear squeeze or covering dynamic at this time.
• Neutral Sentiment: Amgen’s shares were reported to outperform many peers on a relative-basis despite the intraday decline, indicating sector/stock-specific flows rather than a company-specific collapse. MarketWatch: Outperforms Peers
• Negative Sentiment: Amgen (with peers) is reportedly joining a drug-discount initiative (TrumpRx), which could pressure pricing and margins for certain products if discounts are material. Benzinga: TrumpRx Participation
• Negative Sentiment: Analyst upgrades and MariTide optimism are tempered by exclusivity and long-term earnings debate — unresolved regulatory/IP questions could cap upside until clearer trial and exclusivity outcomes arrive. Yahoo: Exclusivity Concerns

Amgen Trading Down 1.4%

AMGN stock opened at $361.13 on Wednesday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a market capitalization of $194.67 billion, a PE ratio of 25.38, a price-to-earnings-growth ratio of 3.63 and a beta of 0.45. The company’s 50-day simple moving average is $359.26 and its 200 day simple moving average is $326.77. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Analyst Ratings Changes

AMGN has been the subject of several research analyst reports. Oppenheimer set a $400.00 target price on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Cantor Fitzgerald raised their price objective on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Morgan Stanley boosted their price objective on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. Finally, Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $354.00.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.